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Abstract
Rationale Amicrodeletion at locus 15q13.3 is associated with
high incidence rates of psychopathology, including schizo-
phrenia. A mouse model of the 15q13.3 microdeletion syn-
drome has been generated (Df[h15q13]/+) with translational
utility for modelling schizophrenia-like pathology. Among
other deficits, schizophrenia is characterised by dysfunctions
in prefrontal cortical (PFC) inhibitory circuitry and attention.
Objectives The objective of this study is to assess PFC-
dependent functioning in the Df(h15q13)/+ mouse using elec-
trophysiological, pharmacological, and behavioural assays.
Method Experiments 1–2 investigated baseline firing and
auditory-evoked responses of PFC interneurons and pyrami-
dal neurons. Experiment 3 measured pyramidal firing in re-
sponse to intra-PFC GABAA receptor antagonism.
Experiments 4–6 assessed PFC-dependent attentional func-
tioning through the touchscreen 5-choice serial reaction time
task (5-CSRTT). Experiments 7–12 assessed reversal learn-
ing, paired-associate learning, extinction learning, progressive
ratio, trial-unique non-match to sample, and object
recognition.
Results In experiments 1–3, the Df(h15q13)/+ mouse showed
reduced baseline firing rate of fast-spiking interneurons and in
the ability of the GABAA receptor antagonist gabazine to
increase the firing rate of pyramidal neurons. In assays of
auditory-evoked responses, PFC interneurons in the Df
(h15q13)/+ mouse had reduced detection amplitudes and in-
creased detection latencies, while pyramidal neurons showed
increased detection latencies. In experiments 4–6, the
Df(h15q13)/+ mouse showed a stimulus duration-dependent
decrease in percent accuracy in the 5-CSRTT. The impairment
was insensitive to treatment with the partial α7nAChR agonist
EVP-6124. The Df(h15q13)/+ mouse showed no cognitive
impairments in experiments 7–12.
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Conclusion The Df(h15q13)/+ mouse has multiple dysfunc-
tions converging on disrupted PFC processing as measured by
several independent assays of inhibitory transmission and at-
tentional function.
Keywords Copy number variation . 15q13.3 . Animal
model .Chrna7 . Prefrontal cortex . Neurophysiology .
Cognition
Introduction
The 15q13.3microdeletion syndrome (15q13.3DS) is caused by
a rare (∼1:30000 births) (LePichon et al. 2010) copy number
variant (CNV) with hemizygosity of at least seven genes on the
long arm of chromosome 15. The microdeletion is associated
with variable cognitive impairment and psychiatric or neurolog-
ical disorders (Miller et al. 2009), including autism (Pagnamenta
et al. 2009; Ben-Shachar et al. 2009), attention deficit hyperac-
tivity disorder (Miller et al. 2009), obsessive compulsive disor-
der (Melchior et al. 2013), and epilepsy (Helbig et al. 2009).
15q13.3DS is also associatedwith a∼10-fold increase in the risk
of schizophrenia (International Schizophrenia Consortium
2008; Stefansson et al. 2014), making it one of the strongest
known genetic risk factors for the disorder.
Among other alterations, the pathophysiology of schizo-
phrenia is underpinned by imbalances within local prefrontal
cortical (PFC) circuitry, typically observed as reductions in
markers for cortical inhibitory signalling efficacy in histolog-
ical (Lewis et al. 2005) and neurophysiological assays
(Daskalakis et al. 2007; Javitt et al. 2008). Moreover, schizo-
phrenia is characterised by core prefrontal-dependent
Bexecutive^ cognitive impairments (Robbins 1990), perhaps
most notably within the domain of attention (Carter and Barch
2007). Deficits in executive functioning have also been linked
to dysregulated cortical recruitment and asynchronous activity
partly produced by disrupted inhibitory activity during cogni-
tive demand (Bickel and Javitt 2009; Nakazawa et al. 2012).
Indeed, schizophrenia-related dysfunctions observed in mea-
sures of event-related neuronal responses are associated with
attentional impairment (Nieman et al. 2002). The critical
15q13.3 segment also encompasses the CHRNA7 gene, which
is involved in cortical inhibitory transmission (Adams et al.
2012; Lin et al. 2014), regulates schizophrenia-relevant neu-
rophysiological markers (Hajos et al. 2005), and is associated
with attentional dysfunction (Adler et al. 1998; Young et al.
2004). The cognitive phenotypes associated with 15q13.3DS
remain imprecisely defined and unspecific deficits typically
ranging from moderate to mild intellectual disability have
been described (Lowther et al. 2014; Gillentine and Schaaf
2015). The 15q13.3DS has also been associated with atten-
tional impairments that can be independent of general intel-
lectual functioning (Miller et al. 2009).
Preclinical lesion and local microinfusion studies have
shown attentional functioning to be contingent on the activity
in the medial prefrontal cortex (mPFC), including the
prelimbic cortex (PrL) (Muir et al. 1996; Chudasama and
Muir 2001; Passetti et al. 2002) and GABAergic activity in
this area (Paine et al. 2011; Pehrson et al. 2013; Pezze et al.
2014). Recordings in animals during cognitive testing further
indicate that inhibitory PrL-activity correlates with attentional
performance in the 5-choice serial reaction time task (5-
CSRTT) (Totah et al. 2009). We have previously generated a
mouse model of the 15q13.3DS (Df[h15q13]/+) which shows
50% reduction in messenger RNA (mRNA) expression of the
genes in the region and several 15q13.3DS- and
schizophrenia-like phenotypes, including decreases in the am-
plitude of cortical auditory-evoked potentials and aberrant
responding to GABAA receptor (GABAAR) antagonism in
seizure assays (Fejgin et al. 2014).
As part of the NEWMEDS initiative (Innovative
Medicines Initiative Grant Agreement No. 115008), the cur-
rent study tested the translational utility of the Df(h15q13)/+
mouse for schizophrenia-relevant cortical-dependent dysfunc-
tions using multiple parallel experimental approaches. These
approaches includedmeasures of (i) pre-attentative processing
through auditory-evoked neural responses, (ii) higher order
executive attention through the touchscreen 5-CSRTT, and
(iii) mechanistic processes through concurrent intra-PFC
GABAergic pharmacology andmeasures of pyramidal neuron
spontaneous discharge rates.
Methods and materials
Animals
The Df(h15q13)/+ mouse was generated by Taconic Artemis
(Köln, Germany) as previously described (Fejgin et al. 2014).
The Df(h15q13)/+ mice were of a c57BL/6NTac background.
All experiments used male mice. Animals were housed under
a 12-h light/dark cycle with stable temperature and humidity
conditions with ad libitum access to food and water.
Experiments 1–2 investigated baseline and auditory-evoked
neural responses of putative pyramidal cells and interneurons
and used 14 mice (age 10–14 weeks; wild type (WT) N=7,
Df(h15q13)/+ N=7). Experiment 3 analysed pyramidal neu-
ron responses to GABAAR antagonism and used 19 mice (age
10–14 weeks; WT N=10, Df(h15q13)/+ N=9). Experiments
4–12 assessed cognitive functions and used three cohorts of
animals (each cohort: WTN=16, Df(h15q13)/+N=16; age at
start of testing: 10 weeks). Prior to cognitive testing, animals
were food restricted and maintained at about 85 % of their
free-feeding weight. Cohort 1 was tested on the 5-CSRTT
(experiments 4–6) and novel object recognition (experiment
12). Cohort 2 was tested on visual discrimination and reversal
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learning (experiment 7), paired-associate learning (PAL) (ex-
periment 8), trial-unique non-match to sample (TUNL) (ex-
periments 11), and extinction learning (experiment 10).
Cohort 3 was tested on progressive ratio (experiment 9). The
experiments followed the European Union regulation (direc-
tive 2010/63 of 22 September 2010) and UK Animals
(Scientific Procedures) Act 1986 and were approved by the
Barcelona School of Medicine Institutional Animal Care and
Use Committee and the DanishNational Committee for Ethics
in Animal Experimentation.
Experiments 1–2: cortical auditory-evoked neuronal
firing
Surgical procedures Mice were anesthetised with
Sevoflurane (Abbott Scandinavia AB, Solna, Sweden), and
body temperature was maintained at 37 °C by an isothermal
heating pad. A 16-channel array electrode (Innovative
Neurophysiology, Durham, NC) was placed in the PrL at ste-
reotaxic coordinates (from bregma and duramater) AP:
+1.9 mm, L: +0.2 mm, and DV: -1.5 mm according to the
mouse brain atlas (Paxinos and Franklin 2008) and secured
through a set of skull-mounted anchor screws (over the cere-
bellum and contralateral to the prefrontal cortex electrode) and
dental cement (3M relyX unicem self-adhesive universal resin
cement). A small hole for ground wires was drilled adjacent to
the cerebellum anchor screw. Mice were treated with a pro-
phylactic antibiotic (5 mg/kg, s.c., Baytril vet®, 50 mg/ml
Enrofloxacin, Bayer, Germany) and peripheral analgesic
(1.5 mg/kg, s.c., Rimadyl vet®, 50 mg/ml Carprofen, Pfizer,
USA) pre-surgery and for 5 days post-surgery. Mice were
allowed ≥1 week of post-surgical recovery.
Signal acquisition Activity of a large number of PrL neurons
was recorded in freely behaving animals. Single- and multi-
unit activities were recorded using a multichannel recording
system (Plexon Inc. Dallas, TX). Continuously recorded data
was band pass-filtered in order to avoid low frequency activity
and visualise the action potentials. Frequencies below 300 Hz
were filtered to delete the slow components of the raw data,
and the upper cut-off frequency of 9000 Hz was applied to
diminish the noisy appearance of the action potential shape
(Quian Quiroga 2009). After filtering, action potentials were
easily visualised on top of background noise activity and
could be detected by using an amplitude threshold. Storage
threshold for spiking events was three standard deviations of
the peak height histogram of filtered signal. Artifact wave-
forms were removed, and the spike waveform minima were
aligned using the Offline Sorter software (v3.2; Plexon,
Dallas, TX).
Spike sorting and classification Action potentials were
sorted into unit clusters using the Offline Sorter software.
Waveform features used for separating the units were the first
three principal components of the sampled waveforms for a
given dataset. A cluster was classified as a single unit when
<0.3 % of the spikes occurred within a 2-ms refractory period.
To group units in putative cell types, we extracted two features
from the average waveform: valley full width at half maxi-
mum and peak-to-valley time. The waveform features were
plotted and used to classify the units as putative pyramidal
cells or putative fast-spiking interneurons (Barthó et al.
2004) (see Supplementary Fig. 1a). Waveforms with a valley
full width at half maximum duration <0.35 ms and valley to
peak time <0.2 ms were considered interneurons, while wave-
forms with a half amplitude duration >0.37 ms and valley to
peak time >0.15 ms were considered pyramidal cells.
Waveforms not falling into one of the two groups were con-
sidered as intermediates and were not included for further
analysis.
Auditory gating paradigm Mice were tested in the dark
phase and were habituated to the recording chamber for
40 min prior to the beginning of the session. Motor activity
was manually monitored via an infrared camera, and record-
ings were made during resting state where periods with loco-
motor activity were excluded from analysis. Paired white
noise auditory stimuli (white noise, 82 dB, 10 ms duration
with 1 ms rise and fall, inter-stimulus interval 500 ms) were
presented with an inter-pair interval of 10 s, and simultaneous
recordings of single-unit activity were made for 10 min. A
transistor-transistor logic (TTL) pulse 50ms prior to the sound
was used as event mark and saved together with single-unit
data. Startle responses were not observed during the recording
sessions. Peri-stimulus time histograms (PSTH) were con-
structed for each spike train with a bin width of 1 ms. The
average PSTH across units were calculated after baseline sub-
traction (baseline interval: −1.4 to −0.4 s relative to first pulse)
of each unit PSTH. The response amplitude was measured in a
30-ms bin starting 10 ms after the stimulus onset. The latency
was set to the first 1 ms bin that was significantly higher than
the baseline firing rate.
Experiment 3: intra-mPFC GABAAR antagonism
and pyramidal discharge rate
Surgical proceduresMice were anesthetised by acute dose of
chloral hydrate (400 mg/kg i.p) and maintenance dose of
∼1 mg/kg/min i.p using a perfusion pump. A heating pad
maintained body temperature at 37 °C. Single-unit recordings
were performed using glass micropipettes pulled from 2-mm
capillary glass (World Precision Instruments, Sarasota, FL)
and a Narishige PE-2 pipette puller (Tokyo, Japan).
Recorded signals were amplified (×10; Neurodata IR283 am-
plifier, Cygnus Technology Inc., Delaware Water Gap, PA),
post-amplified and filtered (×100; band pass filter: 30 Hz–
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10 kHz) (Cibertec amplifier/filter, Madrid, Spain) and
analysed using a DAT 1401plus interface system (Spike2,
Cambridge Electronic Design, Cambridge, UK).
Intra-mPFC gabazine Spontaneous discharge rates of puta-
tive pyramidal neurons in Df(h15q13)/+ and WT mice were
analysed during control conditions and following local
GABAAR antagonism as described in rat PFC (Lladó-Pelfort
et al. 2012). Electrodes (impedances: 6–12 MΩ) containing
saline 2 M or gabazine (20 mM, dissolved in 0.2 M NaCl;
SR95531, Sigma-Aldrich, St Louis, MO) were placed at ste-
reotaxic coordinates (from bregma) AP: +2.1 mm, L: −0.2–
0.4 mm. Pyramidal neuron discharge was examined in the
same mice in standard (NaCl) or gabazine conditions by
performing track descents in both conditions. Electrode de-
scents were made at DV: −1–2.5 mm (from duramater) ac-
cording to the mouse brain atlas (Paxinos and Franklin
2008). Pyramidal neurons were identified by their electro-
physiological characteristics: (i) duration of the depolarisation
phase of the action potential (average of 10 spikes) and (ii)
discharge rate (Lladó-Pelfort et al. 2012) (see Supplementary
Fig. 1b). Gabazine was chosen due to its superior selectivity
relative to the classical GABAAR antagonist bicuculline
(Debarbieux et al. 1998; Stocker et al. 1999). Electrode tips
(5–7-μm diameter) were broken to a final resistance of 9–
15 MΩ. Gabazine reached recorded neurons through passive
diffusion from the electrode as previously shown for
bicuculline (Steward et al. 1990; Tepper et al. 1995). To obtain
a reliable measure of spontaneous discharge rate, a 5-min re-
cording was made for each putative pyramidal neuron after
which the electrode was descended again.
Experiments 4–6: the 5-choice serial reaction time task
Apparatus The 5-CSRTT experiments used 32 operant
t ouchsc r e en chambe r s (Campden In s t r umen t s ,
Loughborough, UK) extensively described elsewhere
(Horner et al. 2013; Mar et al. 2013).
5-choice serial reaction time task (5-CSRTT) The 5-CSRTT
is a rodent analogue of the human continuous performance
task (CPT) measuring attention in which schizophrenic pa-
tients show impairments (Kahn et al. 2012). The 5-CSRTT
is sensitive to mPFC lesions (Muir et al. 1996; Chudasama
Fig. 1 Prefrontal cortical electrophysiological characterisations of
Df(h15q13)/+ and WT littermates. Data are presented as means ± SEM.
a Baseline firing frequencies. The Df(h15q13)/+ mouse had attenuated
baseline firing frequencies of PrL putative fast-spiking interneurons but
not principal cells. bResponse amplitudes. The Df(h15q13)/+ mouse had
decreased detection amplitude in PrL putative fast-spiking interneurons
but not principal cells. c Neuron onset latencies. The Df(h15q13)/+ had
delayed onset latencies of both pyramidal cells and putative fast-spiking
interneurons following auditory stimulation. d Average cortical putative
fast-spiking interneuron response. Reduced firing rates and delayed onset
of Df(h15q13)/+ prelimbic interneurons relative to WT mice in the
auditory double-click paradigm. e Gabazine-induced elevation of PFC
pyramidal spike frequency. The Df(h15q13)/+ showed decreased
sensitivity to intra-mPFC GABAAR antagonism on pyramidal neuron
spike frequency. Asterisks denote p < 0.05 (*p < 0.05, **p < 0.01,
***p< 0.001)
Psychopharmacology
and Muir 2001; Passetti et al. 2002) and perturbations to
mPFC inhibitory signalling in the rodent (Paine et al. 2011;
Pehrson et al. 2013; Pezze et al. 2014) and impulsive and
attentional impairments in mouse models of neuropsychiatric
disorders (Young et al. 2004; Hoyle et al. 2006; Romberg et al.
2011). The task is described in extensive detail elsewhere
(Mar et al. 2013). Briefly, animals were initially trained to
respond to a white-square stimulus using a 2-s stimulus dura-
tion (SD), 40-trial session length, and 5-s delay. Once the
animals had acquired the criterion of ≥80 % accuracy and
≤20 % for two consecutive sessions, they were tested on a
series of probe tests. Each probe test lasted for two consecu-
tive sessions, and the presented data represents the means for
these 2 days (Romberg et al. 2011). These probe tests were
always presented in order of increasing difficulty (i.e., SD
probes were presented in order of decreasing durations, and
delay probes were presented in order of increasing delays).
During probe tests the animals were tested for 7 days a week.
Between each probe test, the animals had to reacquire the
criteria of ≥80 % accuracy and ≤20 % omissions for two
consecutive sessions on the baseline task parameters of 2-s
SD and 5-s delay. These baseline sessions were done in order
to reduce potential proactive interference from previous probe
tests (Romberg et al. 2011; Mar et al. 2013).
In experiment 4, the animals were initially tested on probe
tests of increasing attentional demand by decreasing SDs (1.6,
1.0, 0.8, 0.6, 0.4, 0.2 s). Animals were then given tests of
motor impulsivity by increasing delays (7, 9, 11, 13 s). Next,
the animals were given tests of vigilance through increased
session lengths (80 trials, followed by 140 trials). At each of
these session lengths, the animals were tested on decreasing
SDs (1.6, 1, 0.8, 0.6 s). In experiment 5, the test of 140 trials
per session was repeated using 1.6, 1, 0.8, 0.6, 0.4, and 0.2 s
SDs.Moreover, much recent focus has been on the therapeutic
potentials of the partial α7 nicotinic acetylcholine receptor
(α7nAChR) agonist EVP-6124 against the cognitive deficits
of schizophrenia (Garay et al. 2016). In experiment 6, animals
were treated with EVP-6124 (Latin-square design; 0, 3, 10,
30 mg/kg, 10 ml/kg, 30 min pre-treatment time, i.p; EnVivo
Pharmaceuticals) and tested again on the 140 trials, 0.8-s SD,
and 5-s delay parameter. Each dose-phase was separated by
48 h. Animals were tested drug-free on the baseline parame-
ters (140 trials, 2-s SD, 5-s delay) on sessions separating each
dose-phase. Prior to commencing the Latin-square, animals
were given two saline injections for habituation to the injec-
tion procedure.
The dependent variables were completed trials, percent ac-
curacy (total number of correct trials divided by total number
of correct and incorrect trials), percent omission (total number
of omitted trials divided by the total number of trials), percent
premature responses (total number of premature trials divided
by the total number of trials), percent perseverative correct
(total number of perseverative responses to the correct
location divided by the total number of correct responses),
and average response latency and average reward retrieval
latency. Each session was also divided into 10-trial bins, and
the dependent measures were calculated within each 10-trial
bin.
Experiments 7–12: additional cognitive assays
Apparatus The operant experiments used the same 32
touchscreen chambers that were used in experiments 4–6
(Campden Instruments, Loughborough, UK). The spontane-
ous object recognition experiment used two Y-shaped mazes
made of Perspex.
Additional cognitive assays Experiment 7 assessed discrim-
ination learning and reversal learning in two separate two-
choice challenges; the first using more discriminable stimuli
and the second using more challenging stimuli (see Fig. 3a, b,
inset). The task is described elsewhere (Mar et al. 2013). The
dependent variables for reversal learning were trials to criteri-
on, incorrect responses to criterion, correction trials to criteri-
on, perseverative errors (the number of incorrect responses
made before achieving >50 % correct responding in session),
learning errors (the number of incorrect responses made after
achieving ≤50 % correct responses correct responding in a
session), average response latency, and average reward re-
trieval latency.
Experiment 8 assessed paired-associate learning (PAL).
The task is extensively described elsewhere (Horner et al.
2013). Animals were tested for 70 sessions, and the data was
collapsed into 5-session bins for analyses. The main depen-
dent variables were percent accuracy (expressed as the num-
ber of correct responses divided by the total number of correct
and incorrect responses), correction trials, average response
latency, and average reward retrieval latency.
Experiment 9 assessed touchscreen progressive ratio (PR)
by employing linear ramp schedules of 4, 8, 12, and 16
touches. The task is extensively described elsewhere (Heath
et al. 2015). The dependent variables were the total number of
trials completed, breakpoint (defined as the number of screen
responses emitted in the last successfully completed trial of
the session), the total number of screen touches emitted during
the session, and the number of Bblank^ location touches re-
corded during the session (corrected for total session time).
Experiment 10 assessed touchscreen extinction learning.
The task is extensively described elsewhere (Mar et al.
2013). Within each session, the dependent variables were per-
cent responses (the total number of responses divided by the
number responses and omissions), the number of touchscreen
responses during the ITI, and stimulus response latencies.
Experiment 11 used the touchscreen trial-unique
non-match to sample (TUNL) task to assess working
memory through increasing delays (2, 4, 6, and 8 s)
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followed by tests of decreasing stimuli separations to as-
sess pattern separation (small, medium, large). The task is
extensively described elsewhere (Oomen et al. 2013; Kim
et al. 2015). The dependent variables were percent accu-
racy (total number of correct trials dived by the total
number of correct and incorrect trials), percent correction
trials (total number of correction trials dived by the total
number of correct and incorrect trials), average response
latency, and average reward retrieval latency.
Experiment 12 assessed novel object recognition using 8 h
(trial 1) and 11 h (trial 2 and trial 3) delays. The tasks are
extensively described elsewhere (Winters et al. 2008). Video
analyses of behaviour were made by an experimenter blind to
the genotype and location of the novel object using JWatcher
(version 1.0). For each animal, the discrimination ratio was
calculated (time spent exploring the novel object divided by
the total time spent exploring the objects). Total object explo-
ration times in the sample-phase and object-biases were also
calculated.
Data analyses and statistics
Analyses were done using SPSS (v21.0, IBM Corp, Armonk,
NY). Auditory-evoked neural responses were analysed using
one-way between-subjects ANOVAs. Gabazine effect on py-
ramidal neuron firing was analysed with two-way ANOVA
(with treatment and genotype as main factors). The behaviour-
al data was analysed with repeated measured ANOVAs.
Significant interactions were followed by one-way ANOVAs
or Newman-Keuls post hoc comparisons.
Results
Experiment 1: baseline discharge rates
See Supplementary Figure 1a for waveform features used to
classify units as putative pyramidal cells or putative fast-
spiking interneurons. Df(h15q13/+) mice showed decreased
baseline PrL interneuron discharge rate (Fig. 1a; F1,94= 8.58,
p=0.004). There was no effect of genotype on baseline pyra-
midal neuron discharge rate (F1,334=1.71, p=0.191).
Experiment 2: cortical auditory-evoked neuron response
In the double-click paradigm (Fig. 1b–d), decreased neuron
firing was observed in D(h15q13/+) interneurons (Fig. 1b; F1,
70=6.74, p=0.011) but not pyramidal neurons (F1,239=1.40,
p = 0.238). Df(h15q13/+) interneurons (F1,43 = 6.64,
p=0.013) and pyramidal cells (F1,146=8.82, p=0.003) also
had increased onset latencies (Fig. 1c).
Experiment 3: intra-mPFC GABAAR antagonism
and pyramidal discharge rate
See Supplementary Figure 1b for average action potential du-
rations of cells classified as pyramidal cells. The Df(h15q13/+
) mutant showed decreased pyramidal neuron response to
intra-mPFC GABAAR antagonism (Fig. 1e). A two-way
ANOVA revealed significant main effects of gabazine (F1,
115 = 14.63, p = 0.0002; Ns = 53 and 66 for saline and
gabazine, respectively), and genotype (F1,115 = 12.02,
p= 0.0007; Ns = 67 and 52 for WT and TG, respectively)
and a significant gabazine × genotype interaction (F1,
115=6.23, p=0.020). Post hoc analysis (Newman-Keuls) re-
vealed a significant difference in firing rates between gabazine
and standard recording conditions inWTmice (0.97±0.26 vs.
3.58±0.59 spikes/s, n=29 and 38, respectively; p<0.00002)
but not in Df(h15q13/+) mice (0.57 ± 0.16 vs. 1.12 ± 0.10
spikes/s; n = 24 and 28, respectively) (Fig. 1e). Hence,
gabazine markedly elevated the discharge of putative pyrami-
dal neurons in the PFC ofWTmice, as previously observed in
rats (Lladó-Pelfort et al. 2012) but not in Df(h15q13/+) mice.
This suggests that the Df(h15q13/+) mouse has altered inhib-
itory neurotransmission in this cortical area.
Experiments 4-6: the touchscreen 5-CSRTT
Df(h15q13/+) mice showed a selective stimulus duration-
dependent accuracy deficit following extended training
(Fig. 2a–d). When manipulating the stimulus duration, there
were no effects of genotype or genotype by stimulus duration
interactions on initial tests using 40- or 80-trial session lengths
(Supplementary Fig. 2a–c). However, reproducible stimulus
duration-dependent impairments were observed following ex-
tended training (∼100 sessions) using 140 trials per session.
Extended training improved the performance of WT animals
thereby producing increased room to detect the performance
decrement of the Df(h15q13)/+ mice (see Supplementary
Fig. 2a–c).
When tested on 140 trials per session, the Df(h15q13/+)
mice showed decreased accuracies at shorter SDs (Fig. 2a,
genotype: F1,29 = 11.08, p = 0.002, genotype × SD: F3,
87=5.92, p=0.001). The Df(h15q13/+) mouse showed lower
accuracies at the 0.8-s (p=0.001) and 0.6-s SDs (p=0.002)
but not at the 1-s (p=0.074) and 2-s SDs (p=0.375). There
were no effects of genotype or genotype×SD interaction on
percent omission (Fig. 2b) or any other behavioural measure
(p≥0.20; Supplementary Table S1). The accuracy impairment
in the Df(h15q13/+) was reproduced in the same cohort of
animals using stimulus durations between 2 and 0.2 s
(Fig. 2c, d). Trial-bin analyses showed that Df(h15q13/+)
mice had impaired accuracy throughout the length of the ses-
sions. Thus, the deficit was not related to impaired vigilance
(Supplementary Fig. 2a-c). No impairment was observed on
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test of increasing delays measuring impulsive responding
(Supplementary Fig. 3d) and the partial α7nAChR agonist
EVP-6124 did not reverse the accuracy impairment in the
Df(h15q13/+) mouse (Table 1).
Experiments 7–12: additional cognitive
Experiment 7—visual discrimination and reversal learn-
ing There was no effect of genotype on visual discrimination
learning (Supplementary Fig. S3a-b; p≥ 0.441) or reversal
learning (Fig. 3a, b; p≥0.080).
Experiment 8—paired-associate learning (PAL) There was
no significant effect of genotype in the PAL task. There was
no effect of genotype or genotype× session interaction on per-
cent accuracy (Fig. 3c; p ≥ 0.103) or correction trials
(Supplementary Fig. 3c; p≥0.061).
Experiment 9—progressive ratio (PR) Genotype did not
affect measures of motivation in the PR task. There was no
effect of genotype or genotype×PR schedule interaction on
trials completed (Fig. 3d; p ≥ 0.321) or break points
(Supplementary Fig. 3e; p≥0.321).
Experiment 10—extinction learning There were no effect of
genotype or genotype × session interaction on percent re-
sponses in extinction learning (Fig 3e; p≥0.385).
Experiment 11—trial-unique non-match to sample
When tested on increasing delays, there was no effect
of genotype or genotype×delay interaction on percent accu-
racy (Fig. 3e; p ≥ 0.692). Similarly, there was no effect
of genotype or genotype× separation interaction when tested
using increasing stimuli separations (Fig. 3e; p≥0.692). There
Fig. 2 Performance of Df
(h15q13)/+ and WT littermates in
the 5-choice serial reaction time
task. Data are presented as means
± SEM. a–b Test 1—decreasing
stimulus durations. The Df
(h15q13)/+ mouse showed lower
accuracies at shorter stimulus
durations (a) but did not differ
from WTs on percent omission
(b). c–d Test 2—decreasing
stimulus durations. The accuracy
impairment in the Df(h15q13)/+
mouse was reproduced using
stimulus durations between 2 and
0.2 s (c). There was again no
effect of genotype on percent
omission (d). Asterisks denote
p< 0.05 (*p< 0.05, **p < 0.01)
Table 1 Effect of systemic EVP-
6124 on 5-CSRTT performance
in WT and Df(h15q13)/+ mice
% accuracy % omission
Dose (mg/kg) WT Df(h15q13)/+ WT Df(h15q13)/+
0 90.45 ± 1.06 85.55 ± 1.46 13.24 ± 1.96 17.07 ± 1.90
1 90.14 ± 0.91 86.84 ± 1.25 13.77 ± 2.29 17.08 ± 1.96
10 90.06 ± 1.14 83.70± 2.02 14.95 ± 1.58 20.33 ± 3.36
30 87.38 ± 1.07 85.02± 1.41 20.88 ± 2.55 22.15 ± 2.77
Animals were tested using a 140-trial session length, 5-s delay, and 0.8-s SD. No effect of EVP-6124 on percent
accuracy (genotype: F1,30 = 8.96, p = 0.004, dose: F3,90 = 2.12, p = 0.104, dose × genotype: F3,90 = 1.51,
p = 0.216). EVP-6124 increased omissions at highest dose relative to vehicle (genotype: F1,30 = 1.97, p = 0.171,
dose: F3,90 = 5.10, p = 0.003, dose × genotype: F3,90 = 0.43, p= 0.735) in both Df(h15q13)/+ and WT animals
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were no effects of genotype on correction trials to criterion in
either test (Supplementary Fig. 4f, g; p≥0.683).
Experiment 12—novel object recognition (NOR) The
Df(h15q13/+) mouse showed impaired novel object recogni-
tion (Fig. 3h). However, this impairment was coupled with
deceased sample exploration times (Fig. 3i) and can therefore
not confidently be ascribed to a memory impairment. At the 8-
h delay, there was no effect of genotype on sample exploration
time or discrimination ratio (p≥0.225). At the 11-h delay, the
Df(h15q13/+) mouse showed decreased discrimination ratios
(trial 2: p=0.120; trial 3: p=0.047) and decreased sample
exploration times (trial 2: p= .036; trial 3: p=0.023).
Discussion
A chromosomal microdeletion at locus 15q13.3 is one of the
largest known risk factors of schizophrenia and represents an
ideal opportunity for back-translational study. We have previ-
ously generated a mouse model of the 15q13.3 microdeletion
(Df(h15q13)/+) (Fejgin et al. 2014), and here, we
characterised it using a variety of neurophysiological, phar-
macological, and behavioural assays across multiple experi-
mental sites. This comprehensive phenotyping revealed
marked medial prefrontal cortical dysfunctions in the
Df(h15q13)/+ model as measured by multiple parallel tests
of inhibitory transmission and attentional functioning. These
dysfunctions were observed as decreased baseline activity of
putative interneuron and reduced interneuron and pyramidal
neuron sensitivity to auditory stimulation. The Df(h15q13)/+
mouse also showed reduced sensitivity to intra-mPFC
GABAAR blockade as measured by pyramidal neuron spike
frequencies and a selective attentional impairment in the pre-
frontal cortical-dependent 5-CSRTT. Furthermore, we show
that the attentional impairment of the Df(h15q13)/+ mouse
is insensitive to systemic treatment with the partial
α7nAChR agonist EVP-6124.
The Df(h15q13)/+ mouse showed reduced putative
fast-spiking interneuron baseline activity and decreased puta-
t ive pyramidal cel l and fast-spiking interneuron
auditory-evoked responses. These dysfunctions have clear
translational relevance to schizophrenia and attentional dys-
function. For example, schizophrenia is associated with neu-
rophysiological dysfunctions in passive sensory stimulation
paradigms (2012) such as pre-attentative measures of mis-
match negativity and repetition positivity (Baldeweg et al.
2004) and N100 amplitudes (Michie et al. 1990) as well as
suppressed P50 gating (Adler et al. 1982), a phenomenon
involving α7nAChRs (Freedman et al. 1997) coded by the
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Fig. 3 Performance of Df(h15q13)/+ and WT littermates on tests of
cognitive flexibility, working memory, motivation and learning and
memory. a Reversal learning test 1—Beasy^ discriminable stimuli. Inset
depicts the stimuli. No effect of genotype on trials to criterion, correction
trials to criterion, errors to criterion, early errors, or late errors (p ≥ 0.080).
b Reversal learning test 2—Bchallenging^ stimuli. No effect of genotype
on trials to criterion, correction trials to criterion, errors to criterion, early
errors, or late errors (p ≥ 0.277). c Paired-associate learning (PAL). No
effect of genotype on percent accuracy (p ≥ 0.103). d Progressive ratio.
No effect of genotype on trials completed (p ≥ 0.321). e Extinction
learning. No effect of genotype on percent responses (p ≥ 0.385). f
TUNL—delay challenge. No effect of genotype on percent accuracy
(p ≥ 0.692). g TUNL—pattern separation challenge. No effect of
genotype on percent accuracy (p ≥ 0.302). h–i Novel object recognition.
The Df(h15q13/+)mouse showed reduced discrimination ratio at the 11-h
delay (trial 2: p= 0.12, trial 3: p= 0.047) and reduced sample exploration
time at the 11-h delay (trial 2: p= .036; trial 3: p= 0.023).Asterisks denote
differences at which p< 0.05 (*p< 0.05)
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CHRNA7 gene for which the Df(h15q13)/+ mouse shows al-
lelic insufficiency (Fejgin et al. 2014). Information processing
deficits also include attenuated attentional allocation-driven
cortical event-related potential P3b amplitudes (Roxborough
et al. 1993; Weisbrod et al. 1999; Ford et al. 2001) and in-
creased latencies of evoked potentials in visual and auditory
paradigms, such as continuous performance tasks (Nieman
et al. 2002) that reflect disrupted GABAergic (Benes and
Berretta 2001) and cholinergic (Baldeweg et al. 2006) signal-
ling efficacy. Reduction in cortical inhibition as measured by
transcranial magnetic stimulation has also been observed in
schizophrenic patients independent of clinical state (Fitzgerald
et al. 2002; Daskalakis et al. 2002; Wobrock et al. 2008; Liu
et al. 2009), and the phenotype is similarly linked to deficient
cortical GABAergic transmission and attentional processes
(Daskalakis et al. 2007). Analogous cortical neurophysiolog-
ical dysfunction of auditory and visual event-related responses
is also found in pharmacological animal models of schizo-
phrenia (Bickel and Javitt 2009). Thus, our data indicate that
the Df(h15q13)/+ mouse has decreased speed of processing
and reduced recruitment of putative fast-spiking interneurons
in the PrL and this phenotype corresponds with observations
in schizophrenia patients. This also parallels our previous ob-
servations of reduced parietal, prelimbic, and hippocampal
oscillatory activity or auditory-evoked potentials in the
Df(h15q13)/+mouse (Fejgin et al. 2014) which in conjunction
with the current data would suggest more systemic speed of
processing deficits in the mutant.
The Df(h15q13)/+ mouse showed prefrontal cortical
GABAAR antagonist hyposensitivity with attenuated increase
of putative pyramidal spike frequency in response to local
(PrL+anterior cingulate) application of the GABAAR antag-
onist gabazine. The data parallel findings of disrupted
GABAergic activity in many schizophrenia-relevant animal
models, including cortical reductions in GABA-related
markers (Morrow et al. 2007; Lodge et al. 2009; Francois
et al. 2009; Ammassari-Teule et al. 2009) and aberrant phar-
macological activation of fast-spiking interneurons (Tseng
et al. 2008). The decreased sensitivity to PFC GABAAR
blockade in Df(h15q13)/+ mice is also in agreement with his-
tological findings in patients with schizophrenia showing re-
duced cortical expressions in a range of GABAergic markers,
including non-pyramidal cells (1991), PV-immunoreactivity
(Beasley and Reynolds 1997), GAD65/67 levels (Akbarian
et al. 1995), and GAT1 (Volk et al. 2001). In sum, the attenu-
ated putative pyramidal response to local GABAAR blockade
in the Df(h15q13)/+ mice is in general agreement with data
showing decreased GABAergic function in schizophrenia pa-
tients. The phenotype is also in agreement with the GABAAR
antagonist hyposensitivity of Df(h15q13)/+ in seizure assays
(Fejgin et al. 2014) and the decreased speed of processing and
reduced baseline firing and decreased recruitment of putative
fast-spiking interneurons in response to auditory stimulation.
We have seen no marked reduction of GABAergic markers
that can account for the observed attenuation of putative inter-
neuron basal activity or the decreased sensitivity of putative
interneuron to auditory stimulation and pyramidal neuron sen-
sitivity to GABAAR antagonism in the Df(h15q13)/+ mouse.
In situ hybridization studies have nevertheless revealed a
small but significant difference in prefrontal GAD expression
in the Df(h15q13)/+ mutant (≤10 %; N. Santana, F. Artigas,
unpublished observations). Notably, disruption of numerous
transmitter processes affect cortical inhibitory control and py-
ramidal neuron sensitivity to GABAergic drugs (Haenschel
and Linden 2001; Javitt et al. 2008; Kjaerby et al. 2014) and
further work will be required to determine more fully the
mechanisms underpinning the prefrontal cortical phenotype
of the Df(h15q13)/+ mouse.
Importantly, the Df(h15q13)/+ mouse also exhibited a se-
lective impairment in accuracy at shorter stimulus durations in
the 5-CSRTT. This impairment was found after repeated test-
ing improved the performance of WT animals which
unmasked the deficit in the Df(h15q13)/+ mouse. The impair-
ment was always observed throughout the sessions and there-
fore not related to reduced vigilance (see Supplementary
Fig. S2a–c). Percent accuracy is considered a primary marker
of attentional control in the 5-CSRTT. Percent omission and
latency measures, which can reflect motivational, sensory, or
motoric factors (Robbins 2002), were unaffected in the
Df(h15q13)/+ mouse. The accuracy impairment was also only
observed at shorter stimulus duration, further indicating that
the phenotype is produced by impaired attention.
Attentional dysfunction is at the core of the cognitive def-
icits of schizophrenia (Marder and Fenton 2004; Carter and
Barch 2007); it can precede other symptoms (Cornblatt et al.
1999), predict disorder development (2001), and be present in
non-affected first-degree relatives (Snitz et al. 2006). Thus, the
observation of similar attentional deficits in the Df(h15q13)/+
mouse suggests that the model carries translational utility
within this cognitive domain with possible relevance for drug
discovery.
An attentional impairment in the 5-CSRTT can also be
predicted by the prelimbic neurophysiological and
GABAergic phenotypes of the Df(h15q13)/+ mouse. In
animals, intra-mPFC administration of GABAAR antago-
nists (Paine et al. 2011; Pehrson et al. 2013; Pezze et al.
2014) and agonists (Paine et al. 2011; Pezze et al. 2014)
decrease percent accuracy in the 5-CSRTT, indicating that
imbalances in cortical inhibitory activity disrupts atten-
tion. Moreover, in a variation of the 5-CSRTT, attenuated
PrL inhibitory activity can predict accuracy while being
unrelated to errors of omissions and premature responding
(Totah et al. 2009). Our observations of attenuated PrL
inhibitory activity together with a selective accuracy im-
pairment in the Df(h15q13)/+ mice are entirely consistent
with this view.
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However, Df(h15q13)/+ and WT animals did not differ in
performance on tasks dependent on cognitive flexibility,
working memory, visuospatial learning, and motivation. The
current behavioural experiments employed a battery approach
where some animals where tested sequentially on multiple
touchscreen tasks, and it may be that response strategies ac-
quired in previous assays proactively interfered with perfor-
mance on later tasks thereby masking more general effects of
genotype on cognition. This is however unlikely.
First, the Df(h15q13)/+ mouse has previously been shown
to exhibit a mild cognitive phenotype; the deletion fails to
affect associative learning, spatial working memory, and sen-
sorimotor gating (Fejgin et al. 2014). Visual discrimination
and reversal learning, spatial working memory, and fear con-
ditioning were also recently found to be unaffected in an al-
ternative mouse model of the 15q13.3DS (D/+) (Kogan et al.
2015). Our observation of normal working memory, discrim-
ination learning, and cognitive flexibility in the Df(h15q13)/+
mutant is in comprehensive agreement with these reports.
Furthermore, reproducible attentional impairments were ob-
served following extended testing in the 5-CSRTT. If extend-
ed testing masks some cognitive phenotypes in the
Df(h15q13)/+ mutant the opposite pattern should be expected,
deficits should be attenuated with repeated testing and not
remain stable across multiple tests.
Moreover, although cortical GABAergic activity is rele-
vant for a wide range of cognitive domains, mPFC-specific
GABAAR antagonism through bicucilline fails to affect rever-
sal learning (Enomoto et al. 2011) and working memory as
assessed in the radial-arm maze (Enomoto et al. 2011) and T-
maze (Herremans et al. 1996). Attentional function therefore
appears particularly sensitive to GABAergic disruption
(Enomoto et al. 2011; Tse et al. 2015). Nevertheless, under
the present conditions, the lack of comprehensive impairment
in these assays may limit the behavioural translational poten-
tial of the Df(h15q13)/+ mouse to attentional dysfunction.
Reduced α7nAChR expression has been advanced as a
possible mechanism underlying the neuropsychiatric pheno-
types of 15q13.3DS (LePichon et al. 2010; Hoppman-Chaney
et al. 2013), and decreased cortical α7nAChR-expression is a
mechanistic candidate for the Df(h15q13)/+ phenotype.
α7nAChRs are expressed in parvalbumin-positive
GABAergic fast-spiking interneurons (Murakami et al.
2013), Chrna7 deletion causes dysregulated cortical inhibito-
ry activity (Adams et al. 2012; Lin et al. 2014), and Chrna7-/-
mice show retarded performance in the 5-CSRTT (Young
et al. 2004; Hoyle et al. 2006; Young et al. 2007).
However, acute dosing with the partial α7nAChR agonist
EVP-6124 did not attenuate the attentional deficit in
Df(h15q13)/+ mice. The lack of acute effect may be explained
by reduced cortical α7nAChR expression leading to insuffi-
cient number of channels to be activated (full agonist treat-
ment or chronic dosing may be required for efficacy) or by
rapid agonist-induced receptor desensitisation leading to func-
tional inactivation of the α7nAChR at the EVP-6124 doses
used. Nevertheless, α7nAChR agonists have often failed to
affect attentional measures in schizophrenic patients (Olincy
et al. 2006; Freedman et al. 2008; Lieberman et al. 2013;
Preskorn et al. 2014; Umbricht et al. 2014) and rodent 5-
CSRTT performance (Grottick et al. 2003; Hahn et al. 2003;
Hoyle et al. 2006). In accordance with this, we found EVP-
6124 to be ineffective against the attentional impairment in the
Df(h15q13)/+ mice. Thus, although decreased α7nAChR ex-
pression may cause cortical neurophysiological and attention-
al deficits, data indicate that α7nAChR agonism does not pro-
duce sufficient efficacy or that the mechanism underlying the
phenotype may be downstream from the α7nAChR receptor
or due to the functional importance of the deletion of other
genes in the CNV region (Fejgin et al. 2014).
In sum, we observed multiple dysfunctions converging on
disrupted medial prefrontal cortical functioning in the
Df(h15q13)/+ mouse. These dysfunctions were observed as
(i) decreased baseline firing and attenuated auditory-evoked
responses of putative inhibitory interneurons and (ii) reduced
putative pyramidal cell sensitivity to local GABAAR antago-
nism and (iii) selective decrease in percent accuracy in the 5-
CSRTT. These data parallel the phenotypes of 15q13.3DS-
related neuropsychiatric disorders and indicate that the
Df(h15q13)/+ mouse has translational relevance for model-
ling some cortical dysfunctions associated with schizophrenia.
Acknowledgments The research leading to these results has received
support from the Innovative Medicine Initiative Joint Undertaking under
grant agreement no. 115008 of which resources are composed of EFPIA
in-kind contribution and financial contribution from the European
Union’s Seventh Framework Programme (FP7/2007-2013). The
Behavioural and Clinical Neuroscience Institute is co-funded by the
Medical Research Council and the Wellcome Trust. This study was also
supported by the Instituto de Salud Carlos III, Centro de Investigación
Biomédica en Red de Salud Mental (CIBERSAM). The authors would
like to thank Mercedes Nuñez, Noemí Jurado, Edita Bulovaitė, Sueda
Tunçak, Lewis Buss, and Diab Ali for the skillful technical assistance.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Adams CE, Yonchek JC, Schulz KM et al (2012) Reduced Chrna7 expres-
sion in mice is associated with decreases in hippocampal markers of
inhibitory function: implications for neuropsychiatric diseases.
Neuroscience 207:274–282. doi:10.1016/j.neuroscience.2012.01.033
Psychopharmacology
Adler LE, Pachtman E, Franks RD et al (1982) Neurophysiological evi-
dence for a defect in neuronal mechanisms involved in sensory
gating in schizophrenia. Biol Psychiat 17:639–654
Adler LE, Olincy A,WaldoM et al (1998) Schizophrenia, sensory gating,
and nicotinic receptors. Schizophr Bull 24:189–202
Akbarian S, Kim JJ, Potkin SG et al (1995) Gene expression for glutamic
acid decarboxylase is reduced without loss of neurons in prefrontal
cortex of schizophrenics. Arch Gen Psychiat 52:258–266
Ammassari-Teule M, Sgobio C, Biamonte F et al (2009) Reelin
haploinsufficiency reduces the density of PV+ neurons in
circumscribed regions of the striatum and selectively alters striatal-
based behaviors. Psychopharmacology 204:511–521. doi:10.1007/
s00213-009-1483-x
Baldeweg T, Klugman A, Gruzelier J, Hirsch SR (2004) Mismatch neg-
ativity potentials and cognitive impairment in schizophrenia.
Schizophrn Res 69:203–217. doi:10.1016/j.schres.2003.09.009
Baldeweg T, Wong D, Stephan KE (2006) Nicotinic modulation of hu-
man auditory sensory memory: evidence from mismatch negativity
potentials. Int J Psychophysiol 59:49–58. doi:10.1016/j.ijpsycho.
2005.07.014
Barthó P, Hirase H, Monconduit L et al (2004) Characterization of neo-
cortical principal cells and interneurons by network interactions and
extracellular features. J Neurophysiol 92:600–608. doi:10.1152/jn.
01170.2003
Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons
are reduced in the prefrontal cortex of schizophrenics. Schizophrn
Res 24:349–355
Benes FM, Berretta S (2001) GABAergic interneurons: implications for un-
derstanding schizophrenia and bipolar disorder. Neuropsychopharmacol
25:1–27. doi:10.1016/S0893-133X(01)00225-1
Ben-Shachar S, Lanpher B, German JR et al (2009) Microdeletion
15q13.3: a locus with incomplete penetrance for autism, mental
retardation, and psychiatric disorders. J Med Genet 46:382–388.
doi:10.1136/jmg.2008.064378
Bickel S, Javitt DC (2009) Neurophysiological and neurochemical ani-
mal models of schizophrenia: focus on glutamate. Behav Brain Res
204:352–362. doi:10.1016/j.bbr.2009.05.005
Carter CS, Barch DM (2007) Cognitive neuroscience-based approaches
to measuring and improving treatment effects on cognition in
schizophrenia: the CNTRICS initiative. Schizophr Bull 33:1131–
1137. doi:10.1093/schbul/sbm081
Chudasama Y, Muir JL (2001) Visual attention in the rat: a role for the
prelimbic cortex and thalamic nuclei? Behav Neurosci 115:417–428
Cornblatt B, Obuchowski M, Roberts S et al (1999) Cognitive and behav-
ioral precursors of schizophrenia. Dev Psychopathol 11:487–508
Daskalakis ZJ, Christensen BK, Chen R et al (2002) Evidence for im-
paired cortical inhibition in schizophrenia using transcranial mag-
netic stimulation. Arch Gen Psychiat 59:347–354
Daskalakis ZJ, Fitzgerald PB, Christensen BK (2007) The role of cortical
inhibition in the pathophysiology and treatment of schizophrenia.
Brain Res Rev 56:427–442. doi:10.1016/j.brainresrev.2007.09.006
Debarbieux F, Brunton J, Charpak S (1998) Effect of bicuculline on
thalamic activity: a direct blockade of IAHP in reticularis neurons.
J Neurophysiol 79:2911–2918
Enomoto T, Tse MT, Floresco SB (2011) Reducing prefrontal gamma-
aminobutyric acid activity induces cognitive, behavioral, and dopa-
minergic abnormalities that resemble schizophrenia. Biol Psychiat
69:432–441. doi:10.1016/j.biopsych.2010.09.038
Fejgin K, Nielsen J, Birknow MR et al (2014) A mouse model that
recapitulates cardinal features of the 15q13.3 microdeletion syn-
drome including schizophrenia- and epilepsy-related alterations.
Biol Psychiat 76:128–137. doi:10.1016/j.biopsych.2013.08.014
Fitzgerald PB, Brown TL, Daskalakis ZJ, Kulkarni J (2002) A transcra-
nial magnetic stimulation study of inhibitory deficits in the motor
cortex in patients with schizophrenia. Psychiat Res 114:11–22
Ford JM, Mathalon DH, Kalba S et al (2001) N1 and P300 abnormalities
in patients with schizophrenia, epilepsy, and epilepsy with
schizophrenialike features. Biol Psychiat 49:848–860. doi:10.
1016/S0006-3223(00)01051-9
Francois J, Ferrandon A, Koning E et al (2009) Selective reorganization
of GABAergic transmission in neonatal ventral hippocampal-
lesioned rats. Int J Neuropsychopharm 12:1097. doi:10.1017/
S1461145709009985
Freedman R, Coon H, Myles-Worsley M et al (1997) Linkage of a neu-
rophysiological deficit in schizophrenia to a chromosome 15 locus.
Proc Natl Acad Sci U S A 94:587–592. doi:10.2307/41247
Freedman R, Olincy A, Buchanan RWet al (2008) Initial phase 2 trial of a
nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047.
doi:10.1176/appi.ajp.2008.07071135
Garay RP, Citrome L, Samalin L et al (2016) Therapeutic improvements
expected in the near future for schizophrenia and schizoaffective
disorder: an appraisal of phase III clinical trials of schizophrenia-
targeted therapies as found in US and EU clinical trial registries.
Expert Opin Pharmacother. doi:10.1517/14656566.2016.1149164
Gillentine MA, Schaaf CP (2015) The human clinical phenotypes of
altered CHRNA7 copy number. Biochem Pharmacol 97:352–362.
doi:10.1016/j.bcp.2015.06.012
Grottick AJ, Haman M, Wyler R, Higgins GA (2003) Reversal of a
vigilance decrement in the aged rat by subtype-selective nicotinic
ligands. Neuropsychopharmacol 28:880–887. doi:10.1038/sj.npp.
1300102
Haenschel C, Linden D (2001) Neurophysiology of cognitive dysfunc-
tion in schizophrenia. In: Ritsner MS (ed) Handbook of schizophre-
nia spectrum disorders: phenotypic and endophenotypic presenta-
tions. Springer, pp 449–480
Hahn B, Sharples CGV, Wonnacott S et al (2003) Attentional effects of
nicotinic agonists in rats. Neuropharmacology 44:1054–1067. doi:
10.1016/S0028-3908(03)00099-6
Hajos M, Hurst RS, Hoffmann WE et al (2005) The selective alpha7
nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-
Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] en-
hances GABAergic synaptic activity in brain slices and restores
auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther
312:1213–1222. doi:10.1124/jpet.104.076968
Heath CJ, Bussey TJ, Saksida LM (2015) Motivational assessment of
mice using the touchscreen operant testing system: effects of dopa-
minergic drugs. Psychopharmacology 1–15. doi: 10.1007/s00213-
015-4009-8
Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A,
Muhle H, de Kovel C, Baker C, von Spiczak S, Kron KL, Steinich
I, zlig-Lie AAK, Leu C, Gaus V, Schmitz B, Klein KM, Reif PS,
Rosenow F, Weber Y, Lerche H, Zimprich F, Urak L, Fuchs K,
Feucht M, Genton P, Thomas P, Visscher F, de Haan GJ, Møller
RS, Hjalgrim H, Luciano D, Wittig M, Nothnagel M, Elger CE,
Nürnberg P, Romano C, Malafosse A, Koeleman BPC, Lindhout D,
Stephani U, Schreiber S, Eichler EE, Sander T (2009) 15q13.3
microdeletions increase risk of idiopathic generalized epilepsy. Nat
Genet 41:160–162. doi:10.1038/ng.292
Herremans AH, Hijzen TH,Welborn PF et al (1996) Effects of infusion of
cholinergic drugs into the prefrontal cortex area on delayed
matching to position performance in the rat. Brain Res 711:102–111
Hoppman-Chaney N, Wain K, Seger PR et al (2013) Identification of
single gene deletions at 15q13.3: further evidence that CHRNA7
causes the 15q13.3 microdeletion syndrome phenotype. Clin
Genet 83:345–351. doi:10.1111/j.1399-0004.2012.01925.x
Horner AE, Heath CJ, Hvoslef-Eide M et al (2013) The touchscreen
operant platform for testing learning and memory in rats and mice.
Nat Protoc 8:1961–1984. doi:10.1038/nprot.2013.122
Hoyle E, Genn RF, Fernandes C, Stolerman IP (2006) Impaired perfor-
mance of alpha7 nicotinic receptor knockout mice in the five-choice
Psychopharmacology
serial reaction time task. Psychopharmacology 189:211–223. doi:
10.1007/s00213-006-0549-2
International Schizophrenia Consortium (2008) Rare chromosomal dele-
tions and duplications increase risk of schizophrenia. Nature 455:
237–241. doi:10.1038/nature07239
Javitt DC, Spencer KM, Thaker GK et al (2008) Neurophysiological
biomarkers for drug development in schizophrenia. Nat Rev Drug
Discov 7:68–83. doi:10.1038/nrd2463
Kahn PV, Walker TM, Williams TS et al (2012) Standardizing the use of
the continuous performance test in schizophrenia research: a valida-
tion study. Schizophrn Res 142:153–158. doi:10.1016/j.schres.
2012.09.009
Kim CH, Romberg C, Hvoslef-Eide M et al (2015) Trial-unique, delayed
nonmatching-to-location (TUNL) touchscreen testing for mice: sen-
sitivity to dorsal hippocampal dysfunction. Psychopharmacology
232:3935–3945. doi:10.1007/s00213-015-4017-8
Kjaerby C, Broberg BV, Kristiansen U, Dalby NO (2014) Impaired
GABAergic inhibition in the prefrontal cortex of early postnatal
phencyclidine (PCP)-treated rats. Cereb Cortex 24:2522–2532.
doi:10.1093/cercor/bht109
Kogan J, Gross A, Shin R (2015) Mouse model of chromosome 15q13. 3
microdeletion syndrome demonstrates features of autism spectrum
disorder. J Neurosci 35:16282–16294. doi:10.1523/JNEUROSCI.
3967-14.2015
LePichon J-B, Bittel DC, Graf WD, Yu S (2010) A 15q13.3 homozygous
microdeletion associated with a severe neurodevelopmental disorder
suggests putative functions of the TRPM1, CHRNA7, and other
homozygously deleted genes. Am J Med Genet 152A:1300–1304.
doi:10.1002/ajmg.a.33374
Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons
and schizophrenia. Nat Rev Neurosci 6:312–324. doi:10.1038/
nrn1648
Lieberman JA, Dunbar G, Segreti AC et al (2013) A randomized explor-
atory trial of an α-7 nicotinic receptor agonist (TC-5619) for cogni-
tive enhancement in schizophrenia. Neuropsychopharm 38:968–
975. doi:10.1038/npp.2012.259
Lin H, Hsu F-C, Baumann BH et al (2014) Cortical parvalbumin
GABAergic deficits with α7 nicotinic acetylcholine receptor dele-
tion: implications for schizophrenia. Mol Cell Neurosci 61:163–
175. doi:10.1016/j.mcn.2014.06.007
Liu S-K, Fitzgerald PB, Daigle M et al (2009) The relationship between
cortical inhibition, antipsychotic treatment, and the symptoms of
schizophrenia. Biol Psychiat 65:503–509. doi:10.1016/j.biopsych.
2008.09.012
Lladó-Pelfort L, Santana N, Ghisi V et al (2012) 5-HT1A receptor ago-
nists enhance pyramidal cell firing in prefrontal cortex through a
preferential action on GABA interneurons. Cereb Cortex 22:1487–
1497. doi:10.1093/cercor/bhr220
Lodge DJ, Behrens MM, Grace AA (2009) A loss of parvalbumin-
containing interneurons is associated with diminished oscillatory
activity in an animal model of schizophrenia. J Neurosci 29:2344–
2354. doi:10.1523/JNEUROSCI.5419-08.2009
Lowther C, Costain G, Stavropoulos DJ et al (2014) Delineating the
15q13.3 microdeletion phenotype: a case series and comprehensive
review of the literature. Genet Med 17:149–157. doi:10.1038/gim.
2014.83
Mar AC, Horner AE, Nilsson S et al (2013) The touchscreen operant
platform for assessing executive function in rats and mice. Nat
Protoc 8:1985–2005. doi:10.1038/nprot.2013.123
Marder SR, Fenton W (2004) Measurement and treatment research to
improve cognition in schizophrenia: NIMH MATRICS initiative to
support the development of agents for improving cognition in
schizophrenia. Schizophrn Res 72:5–9. doi:10.1016/j.schres.2004.
09.010
Melchior L, Bertelsen B, Debes NM et al (2013) Microduplication of
15q13.3 and Xq21.31 in a family with Tourette syndrome and
comorbidities. Am J Med Genet 162:825–831. doi:10.1002/ajmg.
b.32186
Michie PT, Fox AM,Ward PB et al (1990) Event-related potential indices
of selective attention and cortical lateralization in schizophrenia.
Psychophysiology 27:209–227. doi:10.1111/j.1469-8986.1990.
tb00372.x
Miller DT, Shen Y, Weiss LA et al (2009) Microdeletion/duplication at
15q13.2q13.3 among individuals with features of autism and other
neuropsychiatric disorders. J Med Genet 46:242–248. doi:10.1136/
jmg.2008.059907
Morrow BA, Elsworth JD, Roth RH (2007) Repeated phencyclidine in
monkeys results in loss of parvalbumin-containing axo-axonic pro-
jections in the prefrontal cortex. Psychopharmacology 192:283–
290. doi:10.1007/s00213-007-0708-0
Muir JL, Everitt BJ, Robbins TW (1996) The cerebral cortex of the rat
and visual attentional function: dissociable effects of mediofrontal,
cingulate, anterior dorsolateral, and parietal cortex lesions on a five-
choice serial reaction time task. Cereb Cortex 6:470–481. doi:10.
1093/cercor/6.3.470
Murakami K, Ishikawa Y, Sato F (2013) Localization of α7 nicotinic
acetylcholine receptor immunoreactivity on GABAergic interneu-
rons in layers I-III of the rat retrosplenial granular cortex.
Neuroscience 252:443–459. doi:10.1016/j.neuroscience.2013.08.
024
Nakazawa K, Zsiros V, Jiang Z et al (2012) GABAergic interneuron
origin of schizophrenia pathophysiology. Neuropharmacology 62:
1574–1583. doi:10.1016/j.neuropharm.2011.01.022
Nieman DH, Koelman JHTM, Linszen DH et al (2002) Clinical and
neuropsychological correlates of the P300 in schizophrenia.
Schizophrn Res 55:105–113. doi:10.1016/S0920-9964(01)00184-0
Olincy A, Harris JG, Johnson LL et al (2006) Proof-of-concept trial of an
alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:
630–638. doi:10.1001/archpsyc.63.6.630
Oomen CA, Hvoslef-Eide M, Heath CJ et al (2013) The touchscreen
operant platform for testing working memory and pattern separation
in rats and mice. Nat Protoc 8:2006–2021. doi:10.1038/nprot.2013.
124
Pagnamenta AT, Wing K, Sadighi Akha E et al (2009) A 15q13.3
microdeletion segregating with autism. Eur J Hum Genet 17:687–
692. doi:10.1038/ejhg.2008.228
Paine TA, Slipp LE, Carlezon WA (2011) Schizophrenia-like attentional
deficits following blockade of prefrontal cortex GABAA receptors.
Neuropsychopharm 36:1703–1713. doi:10.1038/npp.2011.51
Passetti F, Chudasama Y, Robbins TW (2002) The frontal cortex of the rat
and visual attentional performance: dissociable functions of distinct
medial prefrontal subregions. Cereb Cortex 12:1254–1268. doi:10.
1093/cercor/12.12.1254
Paxinos G, Franklin KBJ (2008) The mouse brain in stereotaxic coordi-
nates. Elsevier Academic Press, London
Pehrson AL, Bondi CO, Totah NKB, Moghaddam B (2013) The influ-
ence of NMDA and GABA(A) receptors and glutamic acid decar-
boxylase (GAD) activity on attention. Psychopharmacology 225:
31–39. doi:10.1007/s00213-012-2792-z
Pezze M, McGarrity S, Mason R et al (2014) Too little and too much:
hypoactivation and disinhibition of medial prefrontal cortex cause
attentional deficits. J Neurosci 34:7931–7946. doi:10.1523/
JNEUROSCI.3450-13.2014
Preskorn SH, Gawryl M, Dgetluck N et al (2014) Normalizing effects of
EVP-6124, an alpha-7 nicotinic partial agonist, on event-related
potentials and cognition. J Psychiatr Pract 20:12–24. doi:10.1097/
01.pra.0000442935.15833.c5
Quian Quiroga R (2009) What is the real shape of extracellular spikes? J
Neurosci Meth 177:194–198. doi:10.1016/j.jneumeth.2008.09.033
Robbins TW (1990) The case of frontostriatal dysfunction in schizophre-
nia. Schizophr Bull 16:391–402
Psychopharmacology
Robbins TW (2002) The 5-choice serial reaction time task: behavioural
pharmacology and functional neurochemistry. Psychopharmacology
163:362–380. doi:10.1007/s00213-002-1154-7
Romberg C, Mattson MP, Mughal MR et al (2011) Impaired attention in
the 3xTgAD mouse model of Alzheimer’s disease: rescue by
donepezil (aricept). J Neurosci 31:3500–3507. doi:10.1523/
JNEUROSCI.5242-10.2011
Roxborough H, Mui r WJ , Blackwood DH et a l (1993 )
Neuropsychological and P300 abnormalities in schizophrenics and
their relatives. Psychol Med 23:305–314. doi:10.1017/
S0033291700028385
Snitz BE, Macdonald AW, Carter CS (2006) Cognitive deficits in unaf-
fected first-degree relatives of schizophrenia patients: a meta-
analytic review of putative endophenotypes. Schizophr Bull 32:
179–194. doi:10.1093/schbul/sbi048
Stefansson H, Meyer-Lindenberg A, Steinberg S et al (2014) CNVs con-
ferring risk of autism or schizophrenia affect cognition in controls.
Nature 505:361–366. doi:10.1038/nature12818
Steward O, Tomasulo R, Levy WB (1990) Blockade of inhibition in a
pathway with dual excitatory and inhibitory action unmasks a capa-
bility for LTP that is otherwise not expressed. Brain Res 516:292–
300. doi:10.1016/0006-8993(90)90930-A
Stocker M, Krause M, Pedarzani P (1999) An apamin-sensitive Ca2+-
activated K+ current in hippocampal pyramidal neurons. Proc Natl
Acad Sci U S A 96:4662–4667
Tepper JM, Martin LP, Anderson DR (1995) GABAA receptor-mediated
inhibition of rat substantia nigra dopaminergic neurons by pars
reticulata projection neurons. J Neurosci 15:3092–3103
Totah NKB, Kim YB, Homayoun H, Moghaddam B (2009) Anterior
cingulate neurons represent errors and preparatory attention within
the same behavioral sequence. J Neurosci 29:6418–6426. doi:10.
1523/JNEUROSCI.1142-09.2009
Tse MT, Piantadosi PT, Floresco SB (2015) Prefrontal cortical
gamma-aminobutyric acid transmission and cognitive
function: drawing links to schizophrenia from preclinical re-
search. Biol Psychiat 77:929–939. doi:10.1016/j.biopsych.
2014.09.007
Tseng KY, Lewis BL, Hashimoto T et al (2008) A neonatal ventral hip-
pocampal lesion causes functional deficits in adult prefrontal cortical
interneurons. J Neurosci 28:12691–12699. doi:10.1523/
JNEUROSCI.4166-08.2008
Umbricht D, Keefe RSE, Murray S et al (2014) A randomized, placebo-
controlled study investigating the nicotinic α7 agonist, RG3487, for
cognitive deficits in schizophrenia. Neuropsychopharmacol 39:
1568–1577. doi:10.1038/npp.2014.17
Volk D, Austin MC, Pierri J et al (2001) GABA transporter-1 mRNA in
the prefrontal cortex in schizophrenia: decreased expression in a
subset of neurons. Am J Psychiat 158:256–265. doi:10.1176/appi.
ajp.158.2.256
WeisbrodM,Hill H, Niethammer R, Sauer H (1999) Genetic influence on
auditory information processing in schizophrenia: P300 in monozy-
gotic twins. Biol Psychiat 46:721–725. doi:10.1016/S0006-
3223(99)00022-0
Winters BD, Saksida LM, Bussey TJ (2008) Object recognition memory:
neurobiological mechanisms of encoding, consolidation and retriev-
al. Neurosci Biobehav Rev 32:1055–1070. doi:10.1016/j.neubiorev.
2008.04.004
Wobrock T, Schneider M, Kadovic D et al (2008) Reduced cortical inhi-
bition in first-episode schizophrenia. Schizophrn Res 105:252–261.
doi:10.1016/j.schres.2008.06.001
Young JW, Finlayson K, Spratt C et al (2004) Nicotine improves
sustained attention in mice: evidence for involvement of the α7
nicotinic acetylcholine receptor. Neuropsychopharmacol 29:891–
900. doi:10.1038/sj.npp.1300393
Young JW, Crawford N, Kelly JS et al (2007) Impaired attention is central to
the cognitive deficits observed in alpha 7 deficient mice. Eur
Neuropsychopharm 17:145–155. doi:10.1016/j.euroneuro.2006.03.008
Psychopharmacology
